Immunization with the RrgB321 fusion protein protects mice against both high and low pilus-expressing Streptococcus pneumoniae populations

Vaccine

Volumn 30, Issue 7, 2012, Pages 1349-1356

  Moschioni, Monica ^a   De Angelis, Gabriella ^a   Harfouche, Carole ^a   Bizzarri, Esmeralda ^a   Filippini, Sara ^a   Mori, Elena ^a   Mancuso, Giuseppe ^b   Doro, Francesco ^a   Barocchi, Michèle A ^a   Ruggiero, Paolo ^a   Masignani, Vega ^a  

^a NOVARTIS VACCINES AND DIAGNOSTICS   (Italy)

^b UNIVERSITY OF MESSINA   (Italy)

Author keywords

In vivo protection; Opsonophagocytic killing assay; Pilus 1 biphasic expression; Protein based vaccine; Streptococcus pneumoniae

Indexed keywords

HYBRID PROTEIN; RRGB321 PROTEIN; UNCLASSIFIED DRUG;

ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; BACTERIUM PILUS; CONTROLLED STUDY; FEMALE; IMMUNIZATION; IN VITRO STUDY; IN VIVO STUDY; MICROBIAL POPULATION DYNAMICS; MOUSE; NONHUMAN; PHAGOCYTOSIS; PHENOTYPE; PRIORITY JOURNAL; RECEPTOR DOWN REGULATION; RECEPTOR UPREGULATION; STREPTOCOCCUS PNEUMONIA; STREPTOCOCCUS PNEUMONIAE;

ANIMALS; CELL LINE, TUMOR; FEMALE; FIMBRIAE PROTEINS; FIMBRIAE, BACTERIAL; GENE EXPRESSION REGULATION, BACTERIAL; HUMANS; IMMUNE SERA; IMMUNIZATION; MICE; MICE, INBRED BALB C; OPSONIN PROTEINS; PHAGOCYTOSIS; PNEUMOCOCCAL INFECTIONS; PNEUMOCOCCAL VACCINES; RABBITS; RECOMBINANT FUSION PROTEINS; STREPTOCOCCUS PNEUMONIAE;

EID: 84856566929     PISSN: 0264410X     EISSN: 18732518     Source Type: Journal    
DOI: 10.1016/j.vaccine.2011.12.080     Document Type: Article

References (24)

1. Fletcher M.A., Fritzell B. Brief review of the clinical effectiveness of PREVENAR against otitis media. Vaccine 2007, 25(March (13)):2507-2512.
2. Kim K.S. Acute bacterial meningitis in infants and children. Lancet Infect Dis 2010, 10(January (1)):32-42.
3. Pelton S.I., Leibovitz E. Recent advances in otitis media. Pediatr Infect Dis J 2009, 28(October (10 Suppl.)):S133-S137.
4. Van der P.T., Opal S.M. Pathogenesis, treatment, and prevention of pneumococcal pneumonia. Lancet 2009, 374(October (9700)):1543-1556.
5. Dagan R. Serotype replacement in perspective. Vaccine 2009, August (27 Suppl. 3):C22-C24.
6. Pilishvili T., Lexau C., Farley M.M., et al. Sustained reductions in invasive pneumococcal disease in the era of conjugate vaccine. J Infect Dis 2010, 201(January (1)):32-41.
7. Lexau C.A., Lynfield R., Danila R., et al. Changing epidemiology of invasive pneumococcal disease among older adults in the era of pediatric pneumococcal conjugate vaccine. JAMA 2005, 294(October (16)):2043-2051.
8. Bogaert D., Hermans P.W., Adrian P.V., Rumke H.C., de G.R. Pneumococcal vaccines: an update on current strategies. Vaccine 2004, 22(June (17/18)):2209-2220.
9. Godfroid F., Hermand P., Verlant V., Denoel P., Poolman J.T. Preclinical evaluation of the Pht proteins as potential cross-protective pneumococcal vaccine antigens. Infect Immun 2011, 79(January (1)):238-245.
10. Gianfaldoni C., Censini S., Hilleringmann M., et al. Streptococcus pneumoniae pilus subunits protect mice against lethal challenge. Infect Immun 2007, 75(February (2)):1059-1062.
11. Aguiar S.I., Serrano I., Pinto F.R., Melo-Cristino J., Ramirez M. The presence of the pilus locus is a clonal property among pneumococcal invasive isolates. BMC Microbiol 2008, 8:41.
12. Basset A., Trzcinski K., Hermos C., et al. Association of the pneumococcal pilus with certain capsular serotypes but not with increased virulence. J Clin Microbiol 2007, 45(June (6)):1684-1689.
13. Moschioni M., Donati C., Muzzi A., et al. Streptococcus pneumoniae contains 3 rlrA pilus variants that are clonally related. J Infect Dis 2008, 197(March (6)):888-896.
14. Moschioni M., De Angelis G., Melchiorre S., et al. Prevalence of pilus encoding islets among acute otitis media Streptococcus pneumoniae isolates from Israel. Clin Microbiol Infect 2010, 16(September (9)):1501-1504.
15. Regev-Yochay G., Hanage W.P., Trzcinski K., et al. Re-emergence of the type 1 pilus among Streptococcus pneumoniae isolates in Massachusetts, USA. Vaccine 2010, 28(July (30)):4842-4846.
16. Harfouche C., Filippini S., Gianfaldoni C., Ruggiero P., Moschioni M., Maccari S., et al. RrgB321, a fusion protein of the three variants of the pneumococcal pilus backbone RrgB, is protective In Vivo and elicits opsonic antibodies. Infect Immun 2012, 80(January (1)):451-460.
17. De Angelis G., Moschioni M., Muzzi A., et al. The Streptococcus pneumoniae Pilus-1 displays a biphasic expression pattern. PLoS One 2011, 6(6):e21269.
18. Basset A., Turner K.H., Boush E., Sayeed S., Dove S.L., Malley R. Expression of the type 1 pneumococcal pilus is bistable and negatively regulated by the structural component RrgA. Infect Immun 2011, 79(August (8)):2974-2983.
19. Alloing G., Martin B., Granadel C., Claverys J.P. Development of competence in Streptococcus pneumonaie: pheromone autoinduction and control of quorum sensing by the oligopeptide permease. Mol Microbiol 1998, 29(July (1)):75-83.
20. Burton R.L., Nahm M.H. Development and validation of a fourfold multiplexed opsonization assay (MOPA4) for pneumococcal antibodies. Clin Vaccine Immunol 2006, 13(September (9)):1004-1009.
21. Barocchi M.A., Ries J., Zogaj X., et al. A pneumococcal pilus influences virulence and host inflammatory responses. Proc Natl Acad Sci U S A 2006, 103(February (8)):2857-2862.
22. Kreikemeyer B., Gamez G., Margarit I., et al. Genomic organization, structure, regulation and pathogenic role of pilus constituents in major pathogenic Streptococci and Enterococci. Int J Med Microbiol 2011, 301(March (3)):240-251.
23. Carbonnelle E., Hill D.J., Morand P., et al. Meningococcal interactions with the host. Vaccine 2009, 27(June (Suppl. 2)):B78-B89.
24. Proft T., Baker E.N. Pili in Gram-negative and Gram-positive bacteria-structure, assembly and their role in disease. Cell Mol Life Sci 2009, 66(February (4)):613-635.